The Conversation (0)
- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
May 28, 2024
Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of a milestone article on its blood test for the accurate and early detection of ovarian cancer.
Highlights
- A benchmarking study comparing CLEO’s ovarian cancer blood test against ultrasound has been published in scientific journal “Cancers”
- The study confirmed that CLEO’s initial test for the surgical triage market:
- Significantly outperforms current clinical workflows that use CA125 and ultrasound to predict malignancy;
- Correctly detected 90% of early-stage cancers compared to only 50% using standard workflows; and
- Can be easily adopted for use into clinical practice.
- The superior performance of CLEO’s test now compared to all current routine clinical tools shows the significant global potential for the test in clinical decision making prior to surgical intervention.
The article, entitled ‘Utility of a Multi-Marker Panel with Ultrasound for Enhanced Classification of Adnexal Mass’ was published in peer reviewed medical journal, “Cancers”.
A copy of the publication is available here: https://www.mdpi.com/2072-6694/16/11/2048
CLEO’s Blood Test Far Superior to Current Standard of Care
The benchmarking study compared CLEO’s ovarian cancer blood test against the current standard clinical workflows that use CA125 and ultrasound to predict malignancy. The outcomes of the study build on previous results (see ASX Announcements 6 November 2023, and 25 March 2024) which clearly demonstrate that CLEO’s ovarian cancer blood test is far superior to all routine clinical tools used by doctors to ‘predict’ the diagnosis of an adnexal mass prior to surgery.
Importantly, CLEO’s test correctly detected 90% of early-stage cancers compared to only 50% using current standard of care workflows of CA125 and ultrasound.
Commenting on the latest study data, CLEO Chief Executive, Richard Allman, said:
“Our peer-reviewed publication strategy is delivering gold-standard clinical evidence which is vitally important as we begin to engage with potential early adopters of our technology.
Having demonstrated now that the CLEO ovarian cancer blood test is far superior to CA125 and ultrasound in our initial pre-surgical triage market, we open up new dialogue with physicians to consider the potential material benefits that CLEO brings for their patients.
More broadly, these encouraging results on early-stage cancer detection provide impetus for us to progress the development of CLEO’s screening test for ovarian cancer.”
Clinical Evidence Supports Commercial Pathway
As a part of CLEO’s commercialisation program, the Company is focusing on a number of initiatives in parallel that will deliver appropriate routes to adoption of its tests following regulatory approval and market launch. CLEO’s publication strategy continues to deliver gold-standard clinical evidence which provides a strategic foundation for clinical implementation and uptake, and critically supports the Company’s case for reimbursement of the blood test to enable early revenue.
Over the past 6 months CLEO has generated significant performance data for its initial test aimed for the pre-surgical triage market. The test has now been benchmarked against all of the routinely available clinical tools which aid in the assessment of an adnexal mass. The Company is pleased to report that our prototype test is superior to all of those existing tools.
Current Standard of Care Inadequate
When a physician identifies a suspected adnexal mass, the patient will typically be referred for ultrasound imaging and a CA125 test to ‘predict’ the risk of malignancy. Ovarian cancers are only diagnosed after extensive and radical surgical intervention, and currently up to 90% of suspected malignancies are post-surgically diagnosed as benign. Conversely, less than half of cancer patients receive primary referral to an oncology surgeon, delaying (and sometimes compromising) their treatment. This is a major failing in the pre-surgical clinical evaluation process that impacts both patient treatment outcomes and the allocation of healthcare resources.
Despite its poor performance CA125 is exclusively recommended in medical guidelines, and represents over $1 billion market with an estimated CAGR ~4%1. Its ubiquitous use has remained largely unchallenged since its introduction in the 1980s.
For this reason, CLEO has focused on generating strong evidence to show doctors how the CLEO test can provide an important and material improvement to their current clinical practice. The test has been developed in a format familiar to clinicians prescribing standard panel blood tests, and will integrate seamlessly into current workflows. It is minimally invasive, economical and will utilise existing pathology lab infrastructure.
Click here for the full ASX Release
This article includes content from CLEO Diagnostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
COV:AU
17 March
CLEO Delivers Commercial Development Milestone
31 January
Quarterly activities and cashflow report
09 December 2024
CLEO Further Expands Ovarian Cancer Trial with Siles Health
26 November 2024
The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
13 March
BlinkLab Completes First Patient Test for US Autism Diagnostic Study
Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.
BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.
The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.
"Launching our US trial marks a very special and important moment for BlinkLab. Our mission has always been to connect fundamental neuroscience with clinical practice through accessible technology, thereby enhancing autism diagnostic evaluations and enabling early intervention for children,” said CEO and Co-founder Dr. Henk-Jan Boele.
According to BlinkLab, the American Academy of Pediatrics advises that all children be screened for autism at 18 to 24 months. This is to refrain from delays in diagnosis, as many children miss critical windows for early intervention.
Dx1’s goal is to address these delays by helping healthcare providers deliver faster and more reliable assessments. The smartphone-based platform uses artificial intelligence to measure sensory sensitivity.
“After extensive app and portal development, stimulus refinement, and testing in hundreds of children, we are very confident in our (Food and Drug Administration) study's potential," Boele added.
Results from the targeted 100 participant study are scheduled for release in the third quarter of 2025. The trial will proceed to the main study thereafter, which aims to test 750 to 900 children.
BlinkLab’s submission for FDA 510(k) clearance is anticipated in 2026.
In 2023, privately held EarliTec Diagnostics came up with a similar innovation for autism detection. The company's creation focuses more on social-visual engagement, evaluating a child’s looking behaviour.
Currently, BlinkLab is the only ASX-listed company focusing on providing autism detection services or applications.
Don’t forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Gabrielle de la Cruz, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: BlinkLab is a client of the Investing News Network. This article is not paid-for content.
Keep reading...Show less
25 February
HeraMED Signs Strategic Collaboration Agreement with Garmin Health
HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.
- HeraMED has executed a collaboration agreement with Garmin;
- Agreement enables integration of Garmin smartwatch data through the Garmin Health API into HeraMED’s clinical grade remote monitoring pregnancy platform, HeraCARE;
- Expansion of the range of health data available to expectant mothers and their healthcare providers;
- HeraMED and Garmin will jointly collaborate on marketing efforts to promote their integrated solutions;
- Collaboration includes exploration of women's health research opportunities
Driven by Garmin Health, a leading provider of digital health solutions that leverage the data and insights of the Garmin product ecosystem, the collaboration will focus on data integration, joint marketing initiatives and exploration of women’s health research. Using the Garmin Health API, pregnant women who consent to sharing their health and fitness activity data through the Garmin Health API can wear Garmin smartwatches and have their health data collected and integrated into the HeraCARE platform, including:
- Expanded health metrics including heart rate, sleep patterns, and fitness activity levels
- Improved continuous monitoring capabilities for pregnant women
- Enhanced data quality and quantity for more informed decision-making
The collaboration will allow HeraCARE users to seamlessly connect their Garmin devices, providing a more comprehensive view of maternal health. This integration is expected to significantly augment the platform's existing capabilities, which include fetal and maternal heart rate monitoring, blood pressure tracking, and mood assessment. This collaboration will have an initial 3-year term with either group having the ability to withdraw by providing 3 months notice.
HeraMED Managing Director and CEO, Anoushka Gungadin, commented: “This is an incredibly exciting collaboration for HeraMED. Garmin is a globally recognised brand that has developed a specific smartwatch technology strategy for women. It is a significant step forward in our mission to revolutionise maternity care. By incorporating Garmin's high-quality sensor data into HeraCARE, we're expanding and enhancing our ability to provide continuous, real-time health insights to expectant mothers and their healthcare providers.
We are delighted to bring health and wellness data into our clinical grade platform for the purpose of transforming the model of care for maternity. The additional data points will contribute to HeraMED’s ‘data- as-an-asset’ approach with the possibility to monitor activities such as steps for pregnant mothers with hypertensive or diabetic conditions or sleep quality for our mental health care plans will only enrich the capability of HeraCARE.”
Garmin Health Senior Director of Global B2B Sales Joern Watzke said: “We are excited to collaborate with HeraMED to leverage Garmin smartwatch technology in support of women’s healthcare. This strategic relationship will highlight how Garmin wearable data can extend beyond informing daily healthy habits to supporting pregnancy monitoring by providing healthcare providers with valuable patient insights. By making smartwatch technology and advanced health data available for a variety of applications in the fields of healthcare, insurance and research, we believe Garmin is truly helping change the future of women’s healthcare for the better.”
In addition to the HeraCARE platform integration, HeraMED and Garmin will explore potential research collaborations and data integrations through the Garmin Health API focused on women’s health, including maternity care. This collaboration is dedicated to research and data rather than commercial and it is intended will develop specific research projects to be supported by targeted granting bodies in key target markets.
This collaboration agreement does not involve any direct financial consideration between the companies. However, HMD anticipates the collaboration is beneficial as it will enhance the HeraCARE platform by providing a more holistic view of maternal health by bringing health and wellness data together, and the additional data points will contribute to HMD's ‘data-as-an-asset’ strategy.
Click here for the full ASX Release
This article includes content from HeraMED Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
17 February
2 Biggest Medical Device ETFs in 2025
Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.
Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.
In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.
To help investors make decisions when it comes to medical device ETFs, here the Investing News Network provides a brief breakdown of what ETFs are and a look at the medical device ETFs you can invest in.
What is an exchange-traded fund?
Exchange-traded funds, or ETFs, hold a basket of equities, often focused on a theme or niche. ETFs are appealing because they give investors the ability to hone in on a specific market area without investing in individual companies. While they are similar to mutual funds, ETFs trade on stock exchanges in the same way stocks do.
Put simply, ETFs reduce the risk of investing by providing access to a larger pool of companies — they let investors pick an area that interests them and suffer less financially if one company under the ETF’s umbrella underperforms. In this way, ETFs allow investors to enter the market confidently and hopefully enjoy long-term capital gains.
Like many areas of the life science space, the medical device sector can be volatile, making ETFs particularly appealing. For example, if a company in a medical device ETF fails a clinical trial or receives negative feedback from the US Food and Drug Administration, ETF investors will largely be protected from any share price drop the stock might have.
On the other hand, if a company in a medical device ETF sees a major gain, that increase will also be muted for ETF investors. That's why some investors prefer to take their chances by adding individual stocks to their portfolios.
Medical device ETFs to consider
Investors keen on medical device ETFs only have three choices, according to ETFdb.com.
Here’s a brief look at the two biggest medical device ETFs available. The third ETF, the First Trust Indxx Medical Devices ETF (BATS:MDEV), is much smaller, with total assets of only US$2.16 million.
1. iShares US Medical Devices ETF (ARCA:IHI)
Total assets: US$5.1 billion
The iShares US Medical Devices ETF was launched in 2006 and tracked 50 holdings as of February 11, 2025. This iShares ETF has more than US$5.1 billion in assets under management and its top three constituents by weight are:
- Abbott Laboratories (NYSE:ABT): Abbott Laboratories’ medical devices are geared towards vascular disease, diabetes and vision care.
- Intuitive Surgical (NASDAQ:ISRG): This medical device firm is the maker of the da Vinci surgical and Ion endoluminal systems. These robotic products are designed to improve clinical outcomes for patients through minimally invasive surgery.
- Boston Scientific (NYSE:BSX): Boston Scientific's device portfolio is extensive. Its areas of focus include gastroenterology, cardiac and vascular surgery, neurological and orthopedic surgeries, and urology.
2. SPDR S&P Health Care Equipment ETF (ARCA:XHE)
Total assets: US$208.99 million
Formed on January 26, 2011, the SPDR S&P Health Care Equipment ETF tracked 66 holdings as of February 11, 2025. This SPDR ETF has more than US$208 million in assets under management and some of its top holdings are:
- Inari Medical (NASDAQ:NARI): Headquartered in California, Inari Medical developed the first mechanical thrombectomy system to receive FDA 510(k) clearance for the treatment of pulmonary embolism.
- AtriCure (NASDAQ:ATRC): Another venous-focused medical device company, AtriCure developed the first medical device to receive FDA approval for the treatment of persistent atrial fibrillation.
- iRhythm Technologies (NASDAQ:IRTC): Medical device firm iRhythym Technologies combines wearable biosensors and cloud-based data analytics with its proprietary algorithms to produce clinical actionable information.
This is an updated version of an article originally published by the Investing News Network in 2016.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Keep reading...Show less
23 January
Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®
Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1
HCA Healthcare operates one of the most comprehensive hospital networks in the US, encompassing over 180 hospitals and approximately 2,400 sites of care in 20 states.
The national contract covering the deployment of Technegas in nuclear medicine departments across the entire HCA network was instigated by HCA after multiple of its sites entered into independent discussions with Cyclopharm regarding Technegas. This prompted HCA head office to initiate the creation of a broad-based contract which will bypass the need for individual site contract negotiations and most efficiently streamline the deployment of Technegas technology.
The agreement further underscores the commercial demand for Technegas which is already the preferred agent of choice in 65 countries outside the US for diagnosing lung conditions, including pulmonary embolism, hypertension, chronic obstructive pulmonary disease (COPD), and other respiratory diseases.
Cyclopharm CEO James McBrayer said, “We are thrilled to partner with HCA Healthcare, a leader in delivering quality care to millions of patients annually. This 3-year agreement will allow for the accelerated availability of Technegas across the US and reinforces our commitment to improving outcomes for patients with respiratory conditions.”
As well as streamlining implentation across up to 169 HCA nuclear medicine departments, today’s agreement opens discussions with the HealthTrust Purchasing Group (HealthTrust)2, HCA’s affiliated group purchasing organisation (GPO) that serves as the contracting and purchasing arm to a further network of over 1,800 hospitals in the USA.
Cyclopharm will now engage directly with individual HCA locations, clinical leaders and Divisional Directors to implement Technegas, prioritising those sites which had already entered preliminary discussions with Cyclopharm.
Technegas has been recognized globally for its ability to provide precise and reliable functional lung imaging. With this contract, HCA facilities will be at the forefront of adopting advanced nuclear medicine technology, ensuring better diagnostic and therapeutic options for their patients.
Mr. McBrayer concluded, “This agreement not only extends the footprint of Technegas in the US market but also sets the stage for its broader adoption within HealthTrust’s extensive network. We are proud to support HCA in its mission to provide exceptional care and are eager to see the positive impact of our technology on patients and clinicians alike.”
Click here for the full ASX Release
This article includes content from Cyclopharm Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
23 January
CONNEQT App Launches in USA as Pulse Deliveries Commence
16 January
Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities
The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.
The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.
Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.
Recent statistics paint a stark picture of the prevalence and burden of these infections. Approximately 75 percent of women experience vulvovaginal candidiasis (VVC) — commonly known as vaginal yeast infection — at some point in their lives, with the annual global prevalence reaching a staggering 134 million cases. The impact is particularly pronounced in developing countries, where the associated morbidity leads to increased healthcare costs and a significant compromise in quality of life for affected women.
The economic ramifications of recurrent VVC are substantial, encompassing both direct costs such as medical visits and medications, and indirect costs related to lost productivity. A study published in the Lancet estimates that in high-income countries, the economic burden attributed to RVVC could reach approximately US$14.39 billion annually. With nearly 500 million women worldwide impacted by VVC, including both initial and recurrent cases, the need for innovative solutions has never been more pressing.
The antifungal market: Gaps and opportunities
Despite the clear need, the current antifungal market faces significant challenges. The limited number of available drug classes — only three primary classes — restricts treatment options and increases the risk of drug resistance.
This situation is exacerbated by rising resistance rates among common fungal genera like Candida and Aspergillus, coupled with a lack of new antifungal classes in development.
The complexity of diagnosing fungal infections often leads to treatment delays, contributing to inappropriate drug use and further increasing the risk of resistance. Moreover, the emergence of drug-resistant fungal species from environmental sources poses additional challenges within clinical settings, underscoring the urgent need for innovative approaches in antifungal therapy development and resistance management.
Advancements in antifungal treatments
Amidst these challenges, recent research has highlighted significant advancements in antifungal treatments specifically addressing women's health concerns. The development of oral oteseconazole, for instance, has shown promising efficacy in clinical trials for recurrent vulvovaginal candidiasis, indicating a potential shift towards more effective management strategies.
Innovative approaches combining antifungal treatments with probiotics aim to restore the natural flora of the vaginal microbiome, offering a holistic solution to improve outcomes for women experiencing recurrent infections. Furthermore, research into new antifungal targets specific to fungal pathogens affecting women has surged, potentially leading to the development of therapies with fewer side effects and improved efficacy against resistant strains.
Zero Candida: Pioneering innovation in women's health
The femtech market, projected to reach nearly $117.37 billion by 2029, represents a golden opportunity for innovative solutions in women's healthcare. At the forefront of antifungal innovation is Zero Candida Technologies (TSXV:ZCT), a company poised to transform the landscape of women's health. Zero Candida is pioneering a SMART diagnostic and therapeutic device designed to provide a chemical-free treatment for candidiasis, aiming to reduce side effects commonly associated with traditional antifungal treatment.
Zero Candida’s groundbreaking approach to treating fungal infections is centred on its innovative device that treats infections without side effects. This aligns perfectly with the growing demand for non-chemical treatments to women's health issues, addressing a critical gap in the current market.
The company's innovative use of AI and blue light technology shines a new light on women's health. In a pre-clinical study, Zero Candida reported an impressive 99.99 percent success rate in treating Candida infections, a significant breakthrough considering that these infections affect 75 percent of women worldwide at some point in their lives.
Market potential and investor interest
The market for women's health and antifungal therapeutics is on a trajectory of significant growth. As of 2023, the global antifungal drugs market was valued at approximately US$15.8 billion, with projections indicating a compound annual growth rate (CAGR) of 3.8 percent from 2024 to 2030. Concurrently, the global women's health therapeutics market is expected to expand to US$61.6 billion by 2032, growing at a CAGR of 4.05 percent from 2024 to 2032.
This growth is driven by increasing awareness of women's health issues, particularly in areas such as reproductive health and menopause-related therapies. The untapped potential in this sector is attracting significant investor interest, with women's health companies reportedly drawing 25 percent of the overall funding market in recent years.
Zero Candida's position at the intersection of antifungal innovation and women's health places it squarely in one of the most dynamic and promising areas of healthcare investment. By addressing the unmet needs in women's health with cutting-edge technology and a focus on non-chemical treatments, Zero Candida is not just participating in the market — it's helping to shape its future.
Investor takeaway
As investor interest grows and market projections continue to climb, the stage is set for a new era in women's health. The potential impact extends far beyond the bottom line, promising improved quality of life for women globally, and a significant reduction in the economic and social burdens associated with these prevalent conditions.
It's clear that the transformative impact of antifungal innovation on women's health is not just a possibility — it's an unfolding reality with profound implications for healthcare, investment and most importantly, the wellbeing of women around the world.
This INNSpired article is sponsored by Zero Candida (TSXV:ZCT). This INNSpired article provides information which was sourced by the Investing News Network (INN) and approved by Zero Candida in order to help investors learn more about the company. Zero Candida is a client of INN. The company’s campaign fees pay for INN to create and update this INNSpired article.
This INNSpired article was written according to INN editorial standards to educate investors.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Zero Candida and seek advice from a qualified investment advisor.
Keep reading...Show less
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00